Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | CNR2 | P34972 | 15/20 | 0.50 |
| ▸ | CNR1 | P21554 | 10/20 | 0.50 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1592413 | 0.95 | CYP3A4 (0.53) | CYP3A4SMN1; SMN2CNR2CNR1NR5A1 | |
| SCHEMBL4074135 | 0.94 | CYP3A4 (0.62) | CYP3A4SMN1; SMN2CNR2CNR1NR5A1 | |
| SCHEMBL10492948 | 0.90 | NR5A1 (0.53) | CNR2CNR1NR5A1LTA4H | |
| SCHEMBL10513794 | 0.89 | NR5A1 (0.56) | CNR2CNR1NR5A1LTA4H | |
| SCHEMBL9776310 | 0.88 | CYP3A4 (0.60) | CYP3A4SMN1; SMN2CNR2CNR1NR5A1 | |
| SCHEMBL29376397 | 0.88 | CYP3A4 (0.60) | CYP3A4SMN1; SMN2CNR2CNR1NR5A1 | |
| SCHEMBL1890228 | 0.86 | CNR2 (0.47) | CYP3A4SMN1; SMN2CNR2CNR1NR5A1 | |
| SCHEMBL4238919 | 0.84 | CNR2 (0.47) | CYP3A4SMN1; SMN2CNR2CNR1NR5A1 | |
| SCHEMBL13298067 | 0.83 | CYP3A4 (0.60) | CYP3A4SMN1; SMN2 | |
| SCHEMBL19978962 | 0.83 | KDM4E (0.52) | CYP3A4SMN1; SMN2NR5A1LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158088-B2 | Extractant compositions for co-extracting cesium and strontium, a method of separating cesium and strontium from an aqueous feed, and calixarene compounds | BATTELLE ENERGY ALLIANCE, LLC (US) | 2012-04-17 | — | — | US | claimed |
| US-20100116749-A1 | EXTRACTANT COMPOSITIONS FOR CO EXTRACTING CESIUM AND STRONTIUM, A METHOD OF SEPARATING CESIUM AND STRONTIUM FROM AN AQUEOUS FEED, CALIXARENE COMPOUNDS, AND AN ALCOHOL MODIFIER | UT-BATTELLE, LLC | 2010-05-13 | — | — | US | claimed |
| US-6174503-B1 | NUCLEAR WASTES TREATMENT, ESPECIALLY WASTES WITH A HIGH CONCENTRATION OF COMPETING ALKALI METAL CATIONS | LOCKHEED MARTIN ENERGY RESEARCH CORPORATION | 2001-01-16 | — | — | US | claimed |
| US-8270554-B2 | Methods of producing cesium-131 | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE UNITED STATES DEPARTMENT OF ENERGY (US) | 2012-09-18 | — | — | US | disclosed |
| US-20100296616-A1 | METHODS OF PRODUCING CESIUM-131 | BATTELLE ENERGY ALLIANCE, LLC (US) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100116749-A1 | EXTRACTANT COMPOSITIONS FOR CO EXTRACTING CESIUM AND STRONTIUM, A METHOD OF SEPARATING CESIUM AND STRONTIUM FROM AN AQUEOUS FEED, CALIXARENE COMPOUNDS, AND AN ALCOHOL MODIFIER | CANX, CBX6, CALD1 | CYP3A4 659/4885SMN1; SMN2 2527/4885CNR2 303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.